Literature DB >> 29065229

Prediction of disease progression in Miller Fisher and overlap syndromes.

Christine Verboon1, Heleen van Berghem1, Pieter A van Doorn1, Liselotte Ruts2, Bart C Jacobs1,3.   

Abstract

Patients with Miller Fisher syndrome (MFS) may have a relatively mild clinical course or progress to Guillain-Barré syndrome (GBS) with limb weakness (MFS-GBS overlap syndrome). Other variants in this spectrum are GBS with ophthalmoparesis and Bickerstaff's Brainstem encephalitis (BBE). To compare the clinical course of MFS and overlap syndromes and to identify predictors of disease progression. In a prospective study of 170 patients with GBS and variant forms, 37 (22%) had a MFS, MFS-GBS overlap syndrome, ophthalmoplegic GBS or BBE. The clinical, serological, and electrophysiological features were compared. Twenty-three patients presented with MFS, of which 10 (43%) developed limb weakness (MFS-GBS overlap syndrome). All these transitions occurred in the first week after onset of symptoms. There were no differences in the clinical, electrophysiological and serological features at entry between MFS and MFS-GBS. Twelve patients had ophthalmoplegic GBS and the disease severity at nadir and outcome was worse than in the patients with a MFS-GBS overlap syndrome. No early predictors for progression from MFS to MFS-GBS overlap syndrome were found. All transitions occurred in the first week. This finding implicates that all patients with MFS need careful monitoring for at least 1 week.
© 2017 Peripheral Nerve Society.

Entities:  

Keywords:  Miller Fisher syndrome; ophthalmoparesis; progression to overlap syndrome

Mesh:

Substances:

Year:  2017        PMID: 29065229     DOI: 10.1111/jns.12238

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  1 in total

1.  Classic and overlapping Miller-Fisher syndrome: clinical and electrophysiological features in Mexican adults.

Authors:  Lisette Bazán-Rodríguez; Juan Carlos López-Hernández; Adib Jorge de Saráchaga; Enrique Gómez-Figueroa; Elizabeth Leon-Manriquez; Maria Eugenia Briseño-Godinez; Raúl May-Mas; Esther Y Pérez-Valdez; Enrique Pérez-Jovel; Steven Vargas-Cañas
Journal:  Neurol Sci       Date:  2021-02-16       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.